Cerevance’s CVN058 Achieves Primary Endpoint In Phase 1b Schizophrenia Cognition Study

Cerevance, a private drug discovery and development company focused on brain diseases, announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia. CVN058 is a novel, brain-penetrant, small-molecule antagonist of the type 3 receptor for serotonin, an important neurotransmitter. The Phase 1b, double-blind, placebo-controlled, three-period cross-over study evaluated CVN058 target engagement in the cerebral cortex by measuring mismatch negativity (MMN) as a pharmacodynamic marker.

Nineteen male and female participants with schizophrenia or . . .